The dermatology market in the U.S. is at a pivotal moment of transformation, with spending poised to climb from $40.55 billion in 2023 to $70 billion by 2030. This unprecedented growth mirrors past ...

Key Facts. Biosimilars are near-identical versions of biologic cancer drugs, available at lower costs. Germany saves hundreds of millions annually from just one biosimilar drug.

Switching from one biosimilar medication to another is safe and effective, ... "The studies were heterogeneous in size, design, and endpoints, providing data on safety, effectiveness, ...

Changes to benefit design, ... Barsell A, Rengifo-Pardo M, Ehrlich A. A survey assessment of US dermatologists’ perception of biosimilars. J Drugs Dermatol. 2017;16(6):612-615. 12.

This episode of the Drug Solutions Podcast will give an overview of the biosimilars market. Industry experts will discuss regulatory controls, pricing pressure, the state of the healthcare industry, ...

The launch of eight adalimumab biosimilars so far this year ended Humira's 20-year monopoly, but it's not clear yet if these discounted drugs will save patients money.

Study Design: Retrospective analysis of commercial pharmacy claims and pharmacy co-payment offsets. ... The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469-478. 4.

Tariffs on US pharma imports could remove discounts offered to health systems by biosimilars and threaten the future of the sector, says a non-profit.

For more information on this research see: Benefit Design and Biosimilar Coverage In Medicare Part D: Evidence and Implications From Recent Reforms. Health Affairs , 2024;43(5):717-724.

Kashiv BioSciences has reported encouraging topline outcomes from the randomised confirmatory trial of the proposed ...